Effect of Roxadustat on Maintenance Hemodialysis Patients with Renal Anemia
Objective:To analyze the effect of Roxadustat on maintenance hemodialysis(MHD)patients with renal anemia.Method:A total of 112 patients with MHD renal anemia admitted to Jinan Weigao Nephrology Hospital from January 2022 to December 2023 were prospectively selected.They were divided into control group and observation group according to random number table method,with 56 cases in each group.The control group was treated with Recombinant Human Erythropoietin Injection,and the observation group was treated with Roxadustat.The clinical efficacy,anemia indexes,iron metabolism indexes,inflammatory factors before and after treatment and adverse reactions were compared between the two groups.Result:The total effective rate of observation group was 92.86%,which was higher than 78.57%of control group,the difference was statistically significant(P<0.05).After treatment,the levels of hemoglobin(Hb),hematocrit(Hct),ferritin(SF)and transferrin saturation(TSAT)were increased in both groups,and the levels of Hb,Hct,SF and TAST in observation group were higher than those in control group,the differences were statistically significant(P<0.05).After treatment,the levels of interleukin-6(IL-6),hypersensitive C-reactive protein(hs-CRP)and tumor necrosis factor-α(TNF-α)in both groups were decreased,and the levels of IL-6,hs-CRP and TNF-α in observation group were significantly lower than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Roxadustat can reduce the inflammatory response of MHD patients with renal anemia,regulate iron metabolism,increase the utilization of endogenous iron,quickly and effectively improve the effect of anemia treatment,and has a certain safety.
万方数据
维普
